Impact of comorbidities on the serological response to COVID-19 vaccination in a Taiwanese cohort

[1]  C. Agrati,et al.  Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV , 2022, Nature Communications.

[2]  Chris Nakas,et al.  Antibody titers after a third dose of the SARS‐CoV‐2 BNT162b2 vaccine in immunocompromised adults in Greece: Is a fourth dose necessary? , 2022, Journal of medical virology.

[3]  Philip R. O. Payne,et al.  Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19 , 2022, Scientific Reports.

[4]  G. Antonelli,et al.  Serological Response and Relationship with Gender-Sensitive Variables among Healthcare Workers after SARS-CoV-2 Vaccination , 2022, Journal of personalized medicine.

[5]  Tyng-Yuan Jang.  Liver injury caused by SARS-CoV-2 Delta and Omicron-variant in Taiwan , 2022, Journal of the Formosan Medical Association.

[6]  Tyng-Yuan Jang.  Why cannot Taiwan be COVID-19 free? , 2022, Journal of the Formosan Medical Association.

[7]  R. Halperin,et al.  A third dose of the BNT162b2 mRNA vaccine significantly improves immune responses among liver transplant recipients , 2022, Journal of Hepatology.

[8]  Henrik Nielsen,et al.  Characteristics associated with serological COVID-19 vaccine response and durability in an older population with significant comorbidity: the Danish Nationwide ENFORCE Study , 2022, Clinical Microbiology and Infection.

[9]  Ming‐Lung Yu,et al.  Clinical characteristics and treatment outcomes of SARS-CoV-2 delta variant outbreak, Pingtung, Taiwan, June 2021 , 2022, Journal of the Formosan Medical Association.

[10]  A. Hoerauf,et al.  Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm’s COVID-19 Vaccines , 2021, Frontiers in Immunology.

[11]  Anthony Z. Matolek,et al.  Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans — Five Veterans Affairs Medical Centers, United States, February 1–September 30, 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[12]  E. Callaway.  Mix-and-match COVID vaccines ace the effectiveness test. , 2021, Nature.

[13]  Michael I. Mandel,et al.  Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel , 2021, The New England journal of medicine.

[14]  V. Caudwell,et al.  SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis , 2021, American Journal of Kidney Diseases.

[15]  Jinseog Kim,et al.  Age-adjusted Charlson comorbidity index score is the best predictor for severe clinical outcome in the hospitalized patients with COVID-19 infection , 2021, Medicine.

[16]  J. V. Van Eyk,et al.  Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2 , 2021, Nature Medicine.

[17]  Kang Zhang,et al.  COVID-19 in early 2021: current status and looking forward , 2021, Signal Transduction and Targeted Therapy.

[18]  Chris Nakas,et al.  Immunogenicity after the first dose of the BNT162b2 mRNA Covid-19 vaccine: real-world evidence from Greek healthcare workers , 2021, Journal of medical microbiology.

[19]  Chi-kung Ho,et al.  222 days without COVID in Taiwan: what are the reasons for this success? , 2021, Journal of Travel Medicine.

[20]  R. Olsthoorn,et al.  Structural phylogenetic analysis reveals lineage-specific RNA repetitive structural motifs in all coronaviruses and associated variations in SARS-CoV-2 , 2021, Virus evolution.

[21]  A. Pollard,et al.  What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 , 2020, The Lancet Infectious Diseases.

[22]  N. Wilson,et al.  Potential lessons from the Taiwan and New Zealand health responses to the COVID-19 pandemic , 2020, The Lancet Regional Health - Western Pacific.

[23]  J. A. Cook,et al.  Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study , 2020, Journal of Hepatology.

[24]  K. Bhaskaran,et al.  Factors associated with COVID-19-related death using OpenSAFELY , 2020, Nature.

[25]  K. Bhaskaran,et al.  OpenSAFELY: factors associated with COVID-19 death in 17 million patients , 2020, Nature.

[26]  R. Brook,et al.  Response to COVID-19 in Taiwan: Big Data Analytics, New Technology, and Proactive Testing. , 2020, JAMA.

[27]  Yi-Chi Wu,et al.  The outbreak of COVID-19: An overview , 2020, Journal of the Chinese Medical Association : JCMA.

[28]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[29]  C. Mackenzie,et al.  A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.